The reported statements, read against the company's own industry.
Financials view
Market Capitalization
275.46MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Revenue (TTM)
2.17MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Profit Margin
0.00%
vs Biotechnology peers
Provider-reported. Net Income (TTM) ÷ Revenue (TTM) on this page gives -1789.37%.Updated Oct 28, 2026
Beta
-0.6140x
vs all stocks
Updated Oct 28, 2026
52-Week Change
-30.43%
vs all stocks
Updated Oct 28, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 28, 2026
Market Capitalization
275.46MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Enterprise Value
341.70MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Forward P/E
-2.31x
vs Biotechnology peers
Updated Oct 28, 2026
Enterprise to Revenue
157.25x
vs Biotechnology peers
Updated Oct 28, 2026
Enterprise to EBITDA
-7.18x
vs Biotechnology peers
Updated Oct 28, 2026
Profit Margin
0.00%
vs Biotechnology peers
Provider-reported. Net Income (TTM) ÷ Revenue (TTM) on this page gives -1789.37%.Updated Oct 28, 2026
Operating Margin
-1438.04%
vs Biotechnology peers
Updated Oct 28, 2026
Return on Assets (TTM)
-59.64%
vs Biotechnology peers
Updated Oct 28, 2026
Revenue (TTM)
2.17MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Revenue per Share (TTM)
0.0010USDUpdated Oct 28, 2026
Quarterly Revenue Growth
516.00%
vs Biotechnology peers
Updated Oct 28, 2026
Gross Profit (TTM)
-21.39MUSD
vs all stocks (USD)
Updated Oct 28, 2026
EBITDA (TTM)
-47.60MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Net Income (TTM)
-38.88MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Quarterly Earnings Growth (YoY)
516.03%
vs Biotechnology peers
Updated Oct 28, 2026
Operating Cash Flow (TTM)
-48.34MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Levered Free Cash Flow (TTM)
-35.60MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 28, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Oct 28, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 28, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 28, 2026
Revenue
1.38MUSDFY2025 · Dec 31, 2025
Operating Income
-59.91MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-60.70MUSDFY2025 · Dec 31, 2025
Income Tax Expense
-537.00KUSDFY2025 · Dec 31, 2025
Net Income
-60.16MUSDFY2025 · Dec 31, 2025
EBIT
-52.00MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-62.67MUSDFY2025 · Dec 31, 2025
Research & Development
28.79MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
32.51MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
8.70MUSDFY2025 · Dec 31, 2025
EPS (Basic)
-0.0400USDFY2025 · Dec 31, 2025
EPS (Diluted)
-0.0400USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
1.46BSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
1.46BSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-60.16MUSDFY2025 · Dec 31, 2025
Preferred Stock Dividends
1.31MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
-35.84MUSDFY2025 · Dec 31, 2025
Free Cash Flow
-37.34MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
3.04MUSDFY2025 · Dec 31, 2025
Interest Paid
388.00KUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-60.16MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
2.34MUSDFY2025 · Dec 31, 2025
Stock-based Compensation
1.21MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
6.98MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
13.69MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
108.00KUSDFY2025 · Dec 31, 2025
Capital Expenditures
-1.50MUSDFY2025 · Dec 31, 2025
Other Investing Activity
-311.00KUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-1.81MUSDFY2025 · Dec 31, 2025
Long-term Debt Issuance
31.25MUSDFY2025 · Dec 31, 2025
Long-term Debt Payments
-1.27MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
49.30MUSDFY2025 · Dec 31, 2025
Shares Outstanding
1.68BSharesUpdated Oct 28, 2026
Float Shares
1.64BSharesUpdated Oct 28, 2026
Shares Short
11.10MSharesUpdated Oct 28, 2026
Short Ratio
4.76days
vs all stocks
Updated Oct 28, 2026
Short % of Shares Outstanding
11.84%
vs all stocks
Provider-reported. Shares Short ÷ Shares Outstanding on this page gives 0.66%.Updated Oct 28, 2026
% Held by Insiders
4.11%
vs all stocks
Updated Oct 28, 2026
% Held by Institutions
0.16%
vs all stocks
Updated Oct 28, 2026
Total Cash (MRQ)
595.00KUSD
vs all stocks (USD)
Updated Oct 28, 2026
Total Cash per Share (MRQ)
0.00USDUpdated Oct 28, 2026
Total Debt (MRQ)
56.44MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Current Ratio (MRQ)
0.0350x
vs Biotechnology peers
Updated Oct 28, 2026
Book Value per Share (MRQ)
-0.0270USDUpdated Oct 28, 2026
Total Assets
81.29MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
5.52MUSDFY2025 · Dec 31, 2025
Total Liabilities
141.57MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
75.77MUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
49.87MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
91.70MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
3.04MUSDFY2025 · Dec 31, 2025
Accounts Payable
30.82MUSDFY2025 · Dec 31, 2025
Short-term Debt
42.54MUSDFY2025 · Dec 31, 2025
Other Current Liabilities
207.00KUSDFY2025 · Dec 31, 2025
Long-term Debt
22.29MUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
1.70MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
1.57MUSDFY2025 · Dec 31, 2025
Retained Earnings
-1.50BUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
-60.28MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
12.00KUSDFY2025 · Dec 31, 2025
52-Week Low
0.1400USDUpdated Oct 28, 2026
52-Week High
0.3400USDUpdated Oct 28, 2026
52-Week Change
-30.43%
vs all stocks
Updated Oct 28, 2026
Beta
-0.6140x
vs all stocks
Updated Oct 28, 2026
50-Day MA
0.1638USDUpdated Oct 28, 2026
200-Day MA
0.2024USDUpdated Oct 28, 2026
Avg 10-Day Volume
5.05MSharesUpdated Oct 28, 2026
Avg 30-Day Volume
4.93MSharesUpdated Oct 28, 2026
Diluted EPS (TTM)
-0.0300USDUpdated Oct 28, 2026
Other Income / Expense
7.91MUSDFY2025 · Dec 31, 2025
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.04×, lower than 95% of its Biotechnology peers (median 5.6×)Significant
Current ratio: 0.04Industry median: 5.60Industry P5: 1.03Peers compared: 245
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.56
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $2.17M, lower than 95% of all stocks globallySignificant
Revenue (USD): 2,173,000Global P5: 37,231,057.061
Companies that share the same coordination system — how they create, deliver, or capture value.